Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal Post author:Sam Post published:December 26, 2017 Post category:BioPharma Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace You Might Also Like Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic December 12, 2017 argenx Bags $231M in Upsized U.S. IPO December 13, 2017 Mysterious NuBiyota Inks Lease for Former Pfizer Campus December 7, 2017
Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic December 12, 2017
